Alnylam Pharmaceuticals, Inc.Equity-NMS: ALNY
Equity-NMS: ALNY
$151.09
-4.14
(9:00 pm IST)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$151.09
Open
$151.09
Today’s high
$157.52
Today’s low
$149.00
52W low
$143.52
52W high
$218.88
1Y
-22.68%
5Y
12.09%
PE
-44.41
EPS (TTM)
-3.52
Shares O/S
125.95M
Market cap
19.03B
Insights
ALNY price is above its 200 day moving average
ALNY PE is in the top end of its range over the past 2 years
In beta. Send feedback here.
Compare with other stock
Price
1D
PE
Market cap
About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.

Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. .


FAQs

Can I buy Alnylam Pharmaceuticals, Inc. shares in India?
How to buy Alnylam Pharmaceuticals, Inc. shares in India?
What is the share price of Alnylam Pharmaceuticals, Inc.?
What is the Market Capitalization of Alnylam Pharmaceuticals, Inc.?
What is the PE ratio of Alnylam Pharmaceuticals, Inc.?
Is Alnylam Pharmaceuticals, Inc. a good stock to buy?
In which sector / industry does Alnylam Pharmaceuticals, Inc. operate?